07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mycobacterium tuberculosis decaprenyl-phosphate N-acetylglucosaminephosphotransferase (rfe; wecA); M. tuberculosis phospho-N-acetylmuramoyl-pentap

Infectious disease INDICATION: Tuberculosis In vitro and cell studies suggest muraymycin D1-based, dual inhibitors of Mycobacterium tuberculosis rfe and murX could help treat tuberculosis (TB). In in vitro enzymatic assays, the antibiotic muraymycin D1 and...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

Health Discovery Corporation, NeoGenomics deal

NeoGenomics received an exclusive, worldwide license to Health Discovery's IP portfolio to develop laboratory developed tests (LDTs) and other products for hematopoietic and solid tumor cancers, excluding retinal and breast cancer. The portfolio consists of...